Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic Effects
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Sodium-glucose cotransporter 2 inhibition with canagliflozin decreases HbA1c, body weight, BP, and albuminuria, implying that canagliflozin confers renoprotection. We determined whether canagliflozin decreases albuminuria and reduces renal function decline independently of its glycemic effects in a secondary analysis of a clinical trial in 1450 patients with type 2 diabetes receiving metformin and randomly assigned to either once-daily canagliflozin 100 mg, canagliflozin 300 mg, or glimepiride uptitrated to 6–8 mg. End points were annual change in eGFR and albuminuria over 2 years of follow-up. Glimepiride, canagliflozin 100 mg, and canagliflozin 300 mg groups had eGFR declines of 3.3 ml/min per 1.73 m 2 per year (95% confidence interval [95% CI], 2.8 to 3.8), 0.5 ml/min per 1.73 m 2 per year (95% CI, 0.0 to 1.0), and 0.9 ml/min per 1.73 m 2 per year (95% CI, 0.4 to 1.4), respectively ( P <0.01 for each canagliflozin group versus glimepiride). In the subgroup of patients with baseline urinary albumin-to-creatinine ratio ≥30 mg/g, urinary albumin-to-creatinine ratio decreased more with canagliflozin 100 mg (31.7%; 95% CI, 8.6% to 48.9%; P =0.01) or canagliflozin 300 mg (49.3%; 95% CI, 31.9% to 62.2%; P <0.001) than with glimepiride. Patients receiving glimepiride, canagliflozin 100 mg, or canagliflozin 300 mg had reductions in HbA1c of 0.81%, 0.82%, and 0.93%, respectively, at 1 year and 0.55%, 0.65%, and 0.74%, respectively, at 2 years. In conclusion, canagliflozin 100 or 300 mg/d, compared with glimepiride, slowed the progression of renal disease over 2 years in patients with type 2 diabetes, and canagliflozin may confer renoprotective effects independently of its glycemic effects.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, SGLT2 inhibitors reduce kidney tubular glucose reabsorption, weight, systemic blood pressure, intraglomerular pressure, and albuminuria and slow GFR loss through mechanisms that appear independent of glycemia (31,(97)(98)(99)(100)(101).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [98]
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Self-citationLevey, A. S., Inker, L. A., Matsushita, K., Greene, T., Willis, K., Lewis, E., de Zeeuw, D., Cheung, A. K., & Coresh, J. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.07.030 · Cited by 620
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Research works printed but not linked: 1
- 2015, Standards of medical care in diabetes–2015., Diabetes Care, 38, S1
Cited by
Items 301–360 of 360
New Tubulocentric Insights for Diabetic Nephropathy: From Pathophysiology to Treatment
Kim, S. S., Kim, J. H., Lee, S. M., Kim, I. Y., & Song, S. H. (2018) · InTech eBooks · doi:10.5772/intechopen.79332 · Cited by 1
“After an initial decrease in eGFR, canagliflozin-treated group showed the slower decline of eGFR compared with glimepiridetreated group over 2 years independently of glycemic effects [104].”
MethodWulandari, V., Trusda, S. A. D., & Nilapsari, R. (2021) · Jurnal Integrasi Kesehatan & Sains · doi:10.29313/jiks.v3i1.7478 · Cited by 1
Sukiatno, L., Kusuma, I. Y., & Samodra, G. (2021) · International Conference on Health and Medical Sciences (AHMS) · doi:10.2991/ahsr.k.210127.027 · Cited by 2
“Reduced intraglomerular pressure can cause a decrease in albuminuria and glomerular filtration rate (Figure 4) [14], [27].”
BackgroundRossing, P. R., & Persson, F. (2021) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2021.06.002 · Cited by 1
SGLT-2 Inhibitors: Drug Selection by Means of the System of Objectified Judgement Analysis Method
Janknegt, R., Reinders, M., & Bianchi, R. (2021) · Acta Scientific Pharmaceutical Sciences · doi:10.31080/asps.2021.05.0750
Zhou, Y., Wang, F., Wen, F., Li, C., & Ye, T. (2023) · Research Square · doi:10.21203/rs.3.rs-2453557/v1 · Cited by 1
Renale und kardiale Effekte von SGLT2-Inhibitoren
Menne, J. (2017) · Der Nephrologe · doi:10.1007/s11560-016-0132-8
“Zumindest konnte kürzlich gezeigt werden, dass es auch nach Gabe von Canagliflozin über einen Zeitraum von 2 Jahren zu einer Stabilisierung der Nierenfunktion im Vergleich zu mit Glimeperid behandelten Patienten kommt [6].”
BackgroundEinfluss von Empagliflozin auf die Albuminurie in der EMPA-REG OUTCOME-Studie
Ebert, T. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0261-3
“Die Frage bleibt daher, ob es ein „renales Gedächtnis“ unter SGLT-2Hemmung gibt, ähnlich denErgebnissen der STENO-2-Studie [7].”
BackgroundSolano, J. N., & Chen-Ku, C. H. (2020) · Acta Médica Costarricense · doi:10.51481/amc.v60i2.997 · Cited by 1
“36 En los resultados se demostró una declinacion sobre la TFG estimada con glimepiride de 3,3 ml/min/1,73m 2 , canagliflozina de 100 mg un 0,5 ml/min/1,73m 2 y canagliflozina 300 mg un 0,9 ml/min/1,73m 2 .”
BackgroundTRATAMIENTO FARMACOLÓGICO DE LA DIABETES MELLITUS PARA PACIENTES CON ENFERMEDAD RENAL
Aranguren, M. F. (2018) · Revista de la Sociedad Argentina de Diabetes · doi:10.47196/diab.v51i3.107
Pharmacologic Renal Protection
Hussein, W. F., & Stack, A. G. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0010
Sodium Glucose Cotransporter-2 Inhibition and Renal Function
Rajasekeran, H. (2018) · TSpace (University of Toronto)
SGLT 2 inhibitors: Antidiabetic agents with promising effects beyond glucose control
Ersoy, C. (2020) · Turkish Journal of Internal Medicine · doi:10.46310/tjim.674514
Wilkinson, S. (2020) · LSHTM Research Online (London School of Hygiene and Tropical Medicine) · doi:10.17037/pubs.04656434
Extending the use of SGLT2 inhibitors from diabetic to non-diabetic kidney disease
Dekkers, C. C. J. (2020) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.136049658
Ganesananthan, S., Woo, T., & Li, C. (2020) · JAMA Surgery · doi:10.1001/jamasurg.2020.5177
Opingari, E. (2019) · TSpace (University of Toronto)
Baito, Q. N., Al-Hassani, A. N., & Al-Nimer, M. S. M. (2021) · Clinical Diabetology · doi:10.5603/dk.a2021.0033
“Previous studies showed that glimepiride can impair renal function, while long term therapy with canagliflozin slowly reduced the renal function, which is dose-independent [28].”
Gliflozins slow down the progression of diabetic kidney disease
Tesař, V., & Vachek, J. (2017) · Vnitřní lékařství · doi:10.36290/vnl.2017.143
Лебедев, Д. А., Тимкина, Н. В., Каронова, Т. Л., Андреева, А., Kokina, M. A., Grigorieva, A. L., Babenko, A. Y., & Grineva, E. N. (2021) · Osteoporosis and Bone Diseases · doi:10.14341/osteo12718
Research Progress on the Protective Effect of SGLT2 Inhibitor on Kidney
姜, 玉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.125569
Li, F., Duan, J., Geng, J., Liu, Z., & Dong, J. (2021) · Diabetic Nephropathy · doi:10.2478/dine-2022-0012 · Cited by 2
Uremic Toxins: The Role of the Gut and the Kidneys
Courville, K. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.109845 · Cited by 1
Dart, A. B. (2023) · Springer eBooks · doi:10.1007/978-3-031-11665-0_32
der Beek, A. B. V. D. A. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.637600695
Mechanisms of SGLT2 inhibition in the kidney: from mechanism towards biomarker guided therapy
Sen, T. (2023) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.659987622
Xu, D., Yuan, Y., Wen, S., Dong, M., Li, Y., Zhou, M., Yuan, X., Wang, C., Gong, M., & Zhou, L. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4618835
The Use of Canagliflozin in Diabetes Mellitus Type 2 on Renal Outcome: A Systematic Review
Haikal, V., Soelistijo, S. A., Puspa, & Prajitno, J. H. (2024) · Current Internal Medicine Research and Practice Surabaya Journal · doi:10.20473/cimrj.v5i1.50710
Vasoactive Substances as Mediators of Renal Injury
Caceres, P. S., & Rossi, N. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-323-95488-4.00105-4
Gao, Y.-X., Kou, C., & Tan, X. (2025) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2025.118070
Medications for the Management of Chronic Kidney Disease
Tran, E. (2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch25 · Cited by 1
Chronic Kidney Disease and Risk Management
(2025) · American Diabetes Association eBooks · doi:10.2337/9781580408462-ch18
Additional file 1 of Empagliflozin’s role in early tubular protection for type 2 diabetes patients
Zhang, C., Ren, W., Lu, X., Feng, L., Li, J., & Zhu, B. (2024) · Figshare · doi:10.6084/m9.figshare.26756590
Lange, L. B., & Bistrup, C. (2025) · Trials · doi:10.1186/s13063-025-09244-4
“After 1 year of SGLT2i therapy, the initial decline in GFR has been surpassed by fall in GFR in the placebo group; 3 years follow up showed that SGLT2i had significantly reduced risk of ESRD, compared to placebo, and this effect has been observed in non-diabetic patients [17, 24].”
Wang, Y., Wang, Y., Mu, Y., & Cheng, Y. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70413
Toth‐Manikowski, S. M., Hannouneh, Z. A., & Atta, M. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00373-3
Herrington, W. G., & Haynes, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-87862-3.00025-2
Kidney Health for All: Caring for People, Protecting the Planet
Vanholder, R., Abdellatif, D. A., Santos, A. C. S. D., Jr., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, Á., Yadla, M., et al. (2026) · Nephrology and Dialysis · doi:10.28996/2618-9801-2026-1-9-21
Huang, H.-E., Jan, J., Lin, Y.-S., Lin, C.-L., Lin, M.-H., Kuo, T.-Y., Yen, P.-C., Li, C.-Y., & Chang, S. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07446-2
“SGLT2i are well-documented for their renoprotective effects in T2DM patients, with evidence showing reduced progression of renal impairment across different age groups [9, 10, 25–27].”
Berchie, R. O., Inker, L. A., Heerspink, H. J. L., Haaland, B., & Greene, T. (2026) · PLoS ONE · doi:10.1371/journal.pone.0347741
Self-citationKidney Health for All: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Blood Purification · doi:10.1159/000552460
Kidney Health for All: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · The Nephron journals/Nephron journals · doi:10.1159/000552619
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · American Journal of Hypertension · doi:10.1093/ajh/hpag041
Kidney Health for All: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Journal of Renal Care · doi:10.1111/jorc.70065
Kidney Health for All: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Nephrology · doi:10.1111/nep.70230
Kidney health for all: Caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_697_26
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., dos Santos, A. C. S., Correa‐Rotter, R., Natarajan, G., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101382
“13,14 Serum creatinine remains the most widespread marker for routine assessment and monitoring of CKD but lacks sensitivity for early detection, 15 although this is essential to timely and effectively prevent progression.”
Bannuru, R. R., Fazioli, K., Bhave, N. M., de Boer, I. H., Earley, A., ElSayed, N. A., Khunti, K., Navaneethan, S. D., Neumiller, J. J., Noble, M., et al. (2026) · Diabetes Obesity and Cardiometabolic CARE · doi:10.2337/doci26-0001
Newland‐Jones, P., Kar, P., Kelly, B., Mohan, R., Davies, S., Diggle, J., Evans, M., Fernando, K., Hicks, D., Kanumilli, N., et al. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01889-x
“No safety signals for LLAs were identi‑ fied during the subsequent renal outcomes trial, CREDENCE, or post hoc analysis of the CAN‑ VAS and CREDENCE data examining outcomes in individuals with high CV risk and/or CKD [8, 78, 79].”
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Journal of The Egyptian Society of Nephrology and Transplantation · doi:10.4103/jesnt.jesnt_16_26
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., dos Santos, A. C. S., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Nephrology (Saint-Petersburg) · doi:10.36485/1561-6274-2026-30-2-8-18
Yu, Y., Zhang, Q., Zapata-Bravo, E., Platt, R. W., Reynier, P., Yu, O. H. Y., & Filion, K. B. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.71182
“Importantly, these effects appear to be independent of baseline glycemic control [33].”
Kidney Health for All: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., dos Santos, A. C. S., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Journal of the Nephrology Society of Thailand · doi:10.63555/jnst.2026.287777
Kidney Health for all: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., dos Santos, A. C. S., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Canadian Journal of Kidney Health and Disease · doi:10.1177/20543581261487735
Abdelmobdy, A. H., Sarhan, I. I., Mansour, R. M., & Hussein, H. S. (2026) · doi:10.2196/preprints.110277
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Journal of Nephrology · doi:10.1093/joneph/aajag117
Kidney Health for All: Caring for People, Protecting the Planet
Vanholder, R. C., Abdellatif, D. A., Santos, A. C. S. D., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Indian Journal of Transplantation · doi:10.4103/ijot.ijot_70_26
Kidney health for all: caring for people, protecting the planet
Vanholder, R. C., Abdellatif, D. A., dos Santos, A. C. S., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-0162en
“CKD symptoms typically emerge at advanced stages, when therapies often can only delay, not prevent, kidney failure 13,14 .”
Saúde renal para todos: cuidar de pessoas e proteger o planeta
Vanholder, R. C., Abdellatif, D. A., dos Santos, A. C. S., Correa‐Rotter, R., Gopalakrishnan, N., Wang, B., Roumeliotis, S. K., Balducci, A., Haris, A., Yadla, M., et al. (2026) · Brazilian Journal of Nephrology · doi:10.1590/2175-8239-jbn-2026-0162pt
Metadata
- Authors
- Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V.
- Affiliations
- University Medical Center Groningen (NL)
- Janssen Research & Development (United States) (US)
- The University of Sydney (AU)
- Corresponding author
- Heerspink, Hiddo J. L.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-08-18
- Volume
- 28
- Issue
- 1
- Pages
- 368-375
- ISSN
- 1046-6673 (ISSN-L)
- 1533-3450
- PMC
- PMC5198289
- OpenAlex
- W2512006388
- Cited by
- 361
- References
- 22
- Citations by year
- 2026: 30 · 2025: 14 · 2024: 17 · 2023: 28 · 2022: 28 · 2021: 44 · 2020: 41 · 2019: 49 · 2018: 49 · 2017: 51 · 2016: 10
- FWCI
- 53.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, type 2 diabetes, renal function decline, EGFR, albuminuria, glimepiride, metformin, renal protection, glycemic control, albumin-creatinine ratio, dose-response relationship, diabetic nephropathy, secondary prevention, cardiovascular risk reduction, HbA1c
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Albuminuria, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Sulfonylurea Compounds, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.